Clinical Trial Update: A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the hypotensive efficacy of AR-12286 ophthalmic solution (0.5% and 0.7%) in patients with Exfoliation Syndrome and ocular hypertensio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exfoliation Syndrome
• Glaucoma
• Ocular Hypertension

Drugs mentioned

• AR-12286 ophthalmic solution (AR-12286)

Snippet

Sponsor: Robert Ritch, MD, LLC. | Conditions: Exfoliation Syndrome, Ocular Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-04-24